Expanding Our Reach: Supporting Lone Soldiers and Preparing Our Next Cohort
Update – October 2026

As we continue our work at Liberated Heart, we remain attentive to the evolving needs of IDF veterans living with PTSD. We are glad to share two significant updates regarding our upcoming treatment cohort and new initiatives.
 

Focusing on Lone Soldiers
We are planning a dedicated treatment cohort for lone soldiers who served in the IDF and are living with PTSD. For many of these veterans, being far from family, having limited day-to-day support, and facing the particular challenges of serving as lone soldiers can deepen the isolation, alienation, and disconnection that often follow PTSD.
 

We would like to focus part of our work specifically on this group. The group component is an integral part of our MDMA-assisted psychotherapy, and we believe it may be especially meaningful for lone soldiers by fostering renewed social connection, trust, and a strong sense of belonging.
 

Our Next Cohort and the Changing Needs We Are Seeing
In parallel, we are preparing to begin our next treatment cohort in about eight weeks. Our MDMA supply is expected to arrive in Israel shortly.
 

This next cohort will include six additional veterans, some from the current war and others from earlier conflicts. We are also seeing a gradual change in the people coming to us: more women are seeking treatment, and we are increasingly meeting younger veterans from the current war who are struggling with significant post-traumatic symptoms.
 

Research, Training, and Sustainable Expansion
The next phase of our initiative is critical. We are working to document outcomes across all cohorts through rigorous, long-term follow-up. Our collected data is shared with the Israeli Ministry of Health in an effort to support the legalization of psychedelic-assisted therapy in Israel.

At the same time, we must begin preparing to train experienced trauma therapists in psychedelic-assisted therapy, so that future expansion can be carried out safely and to a consistently high clinical standard. With the possibility that MDMA-assisted therapy could be approved in Israel within the coming months or year, and given the large number of people with combat-related PTSD, we need to prepare for the training of hundreds of therapists. We believe that Emek Medical Center, as a leading clinical institution with direct experience in this treatment, should play a central role in providing practical training grounded in our clinical experience.
We would like to take this opportunity to once again express our heartfelt appreciation for your support of our mission. Your generosity plays an essential role in enabling Liberated Heart to advance MDMA-assisted psychotherapy for combat veterans living with PTSD.